Table 1.
Clinical-Pathologic Status of CCLA Patients (n = 119)
| Characteristics | Patients |
|
|---|---|---|
| N | Percentage | |
| Age | ||
| Median | 48 | |
| Range | 29-69 | |
| Histologic type | ||
| Squamous cell carcinoma | 109 | 92.59% |
| Adenocarcinoma | 10 | 8.41% |
| Tumor size | ||
| ≤ 4 cm | 41 | 34.45% |
| ≥ 4 cm | 71 | 59.66% |
| Without data | 7 | 5.88% |
| Clinical stage (FIGO) | ||
| IB2 | 14 | 11.76% |
| IIA | 1 | 0.84% |
| IIB | 76 | 63.86% |
| IIIA | 1 | 0.84% |
| IIIB | 27 | 22.68% |
| HPV genotyping (frequency) | ||
| Type 16 | 57 | 37.74% |
| Type 18 | 28 | 18.54% |
| Type 45 | 16 | 10.59% |
| Type 33 | 8 | 6.72% |
| Others | 33 | 21.85% |
| Not determined | 9 | 5.96% |
| Patients with HPV co-infection | 33 | 27.73% |
| Patients without HPV co-infection | 77 | 64.70% |
| Not determined | 9 | 7.56 |
| Treatment outcome⁎ | ||
| CR | 79 | 66.38% |
| NR | 36 | 30.25% |
| Without date for desertion | 4 | 3.36% |
⁎
All patients received radiotherapy and cisplatin as coadjuvant (50-Gy external radiation, 35-Gy intracavitary brachytherapy, and six cycles of 40 mg/m2cis-diamminedichloroplatinum(II)).